Momenta Pharmaceuticals Top Management
Momenta Pharmaceuticals employs about 118 people. The company is managed by 28 executives with a total tenure of roughly 301 years, averaging almost 10.0 years of service per executive, having 4.21 employees per reported executive. Analysis of Momenta Pharmaceuticals' management performance can provide insight into the company performance.
| Craig Wheeler CEO CEO and President and Executive Director |
| James Sulat Chairman Independent Chairman of the Board |
Momenta |
Momenta Pharmaceuticals Management Team Effectiveness
The company has return on total asset (ROA) of (30.56) % which means that it has lost $30.56 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (64.36) %, meaning that it created substantial loss on money invested by shareholders. Momenta Pharmaceuticals' management efficiency ratios could be used to measure how well Momenta Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities.Momenta Pharmaceuticals Workforce Comparison
Momenta Pharmaceuticals is considered to be number one stock in number of employees category among related companies. The total workforce of Drug Manufacturers—Specialty & Generic industry is now estimated at about 77,609. Momenta Pharmaceuticals adds roughly 118 in number of employees claiming only tiny portion of equities under Drug Manufacturers—Specialty & Generic industry.
Momenta Pharmaceuticals Insider Trading
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Momenta Pharmaceuticals insiders, such as employees or executives, is commonly permitted as long as it does not rely on Momenta Pharmaceuticals' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Momenta Pharmaceuticals insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Craig Wheeler over a year ago Momenta Pharmaceuticals exotic insider transaction detected |
Momenta Pharmaceuticals Notable Stakeholders
A Momenta Pharmaceuticals stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Momenta Pharmaceuticals often face trade-offs trying to please all of them. Momenta Pharmaceuticals' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Momenta Pharmaceuticals' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| Ganesh Kaundinya | Co-Founder, Chief Scientific Officer and Sr. VP of Research | Profile | |
| Craig Wheeler | CEO and President and Executive Director | Profile | |
| James Sulat | Independent Chairman of the Board | Profile | |
| James Anderson | Senior Vice President - Pharmaceutical Sciences | Profile | |
| John Bishop | Senior Vice President - Pharmaceutical Sciences | Profile | |
| Bruce Leicher | Senior Vice President General Counsel, Secretary | Profile | |
| Jim Anderson | Senior Vice President - Pharmaceutical Sciences | Profile | |
| Santiago Arroyo | Senior Vice President Development and Chief Medical Officer | Profile | |
| James Roach | Senior Vice President - Development, Chief Medical Officer | Profile | |
| Young Kwon | Senior Vice President - Corporate Development and Strategy | Profile | |
| JoAnn Beltramello | Senior Vice President - Human Resources | Profile | |
| Anthony Manning | Senior Vice President - Research | Profile | |
| Ian Fier | Senior Vice President - Program and Project Management | Profile | |
| Michael Franken | President - Biosimilars Business, Senior Vice President | Profile | |
| Scott Storer | CFO, Senior Vice President | Profile | |
| Michelle Robertson | CFO, Principal Financial Officer and Principal Accounting Officer | Profile | |
| Richard Shea | CFO, Sr. VP and Treasurer | Profile | |
| Matthew Ottmer | COO | Profile | |
| Bennett Shapiro | Independent Director | Profile | |
| Georges Gemayel | Director | Profile | |
| Elizabeth Stoner | Independent Director | Profile | |
| JoseCarlos GutierrezRamos | Director | Profile | |
| Corey Fishman | Director | Profile | |
| Bruce Downey | Independent Director | Profile | |
| Steven Gilman | Director | Profile | |
| Marsha Fanucci | Independent Director | Profile | |
| Thomas Koestler | Independent Director | Profile | |
| Alejandra Carvajal | Chief Legal Officer, General Counsel and Secretary | Profile |
Momenta Pharmaceuticals Workforce Analysis
Traditionally, organizations such as Momenta Pharmaceuticals use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Momenta Pharmaceuticals within its industry.Momenta Pharmaceuticals Manpower Efficiency
Return on Momenta Pharmaceuticals Manpower
| Revenue Per Employee | 254.8K | |
| Revenue Per Executive | 1.1M | |
| Net Loss Per Employee | 1.9M | |
| Net Loss Per Executive | 8.1M | |
| Working Capital Per Employee | 2.8M | |
| Working Capital Per Executive | 12M |
Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in estimate. You can also try the Equity Search module to search for actively traded equities including funds and ETFs from over 30 global markets.
Other Consideration for investing in Momenta Stock
If you are still planning to invest in Momenta Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Momenta Pharmaceuticals' history and understand the potential risks before investing.
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Stocks Directory Find actively traded stocks across global markets | |
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
| My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
| Global Correlations Find global opportunities by holding instruments from different markets |